Akero Therapeutics (Nasdaq: AKRO) is a clinical-stage biotechnology company focused on the development and commercialization of transformative treatments for patients with serious metabolic diseases with high unmet medical need. The company's lead program AKR-001 is being evaluated in a Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company's lead drug, efruxifermin, is being studied for its ability to reverse scarring in patients with NASH.
- June 20, 2019 : initial public offering of 5,750,000 shares of common stock at $16.00 per share.
- Ticker: AKRO
About NASH
NASH is a leading cause of liver failure around the world, driven by the growing global epidemic of obesity. NASH is a severe form of non-alcoholic fatty liver disease (NAFLD) characterized by liver cell (hepatocyte) damage, liver inflammation, and fibrosis that can progress to cirrhosis, liver failure, cancer and death.
No comments:
Post a Comment